RT Journal Article
SR Electronic
T1 Individual treatment effect estimation in the presence of unobserved confounding using proxies: a cohort study in stage III non-small cell lung cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.30.21265597
DO 10.1101/2021.10.30.21265597
A1 Wouter A.C. van Amsterdam
A1 Joost. J.C. Verhoeff
A1 Netanja I. Harlianto
A1 Gijs A. Bartholomeus
A1 Aahlad Manas Puli
A1 Pim A. de Jong
A1 Tim Leiner
A1 Anne S.R. van Lindert
A1 Marinus J.C. Eijkemans
A1 Rajesh Ranganath
YR 2021
UL http://medrxiv.org/content/early/2021/10/30/2021.10.30.21265597.abstract
AB Randomized Controlled Trials (RCT) are the gold standard for estimating treatment effects but some important situations in cancer care require treatment effect estimates from observational data. We developed “Proxy based individual treatment effect modeling in cancer” (PROTECT) to estimate treatment effects from observational data when there are unobserved confounders, but proxy measurements of these confounders exist. We identified an unobserved confounder in observational cancer research: overall fitness. Proxy measurements of overall fitness exist like performance score, but the fitness as observed by the treating physician is unavailable for research. PROTECT reconstructs the distribution of the unobserved confounder based on these proxy measurements to estimate the treatment effect. PROTECT was applied to an observational cohort of 504 stage III non-small cell lung cancer (NSCLC) patients, treated with concurrent chemoradiation or sequential chemoradiation. Whereas conventional confounding adjustment methods seemed to overestimate the treatment effect, PROTECT provided credible treatment effect estimates.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work; PJ received consulting fees from Sanfit and Inozyme. TL is co-founder and shareholder of Quantib-U B.V.. The department of radiology at the University Medical Center Utrecht has a research collaboration with Philips Healthcare.Funding StatementWA was supported by the Alexandre Suerman personal PhD stipendium. The Alexandre Suerman stipend had no role in any part of the study design, conduct or reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of University Medical Center Utrecht waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to local privacy regulations, the original patient data cannot be shared. The code that implements the statistical models and model selection procedure will be made publicly available at an online repository.Abbreviations:RCTrandomized controlled trialPROTECTProxy based individual treatment effect modeling in cancerNSCLCnon-small cell lung cancer